Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenon Medical, Inc. filings document its medical-device business, public securities, and material events tied to sacroiliac joint treatment products. Current Reports on Form 8-K cover financial results, unaudited revenue releases, FDA-cleared product updates, and corporate communications related to the Catamaran System and SImmetry® portfolio.
The filing record also discloses securities purchase agreements, senior convertible notes, private placements of common stock and warrants, restricted stock unit grants under the 2022 Equity Incentive Plan, annual meeting voting matters, Nasdaq listing-compliance notices, and amended acquisition disclosures with financial statements and pro forma information for the SiVantage asset acquisition.
Tenon Medical, Inc. filed an Amendment No. 1 to Form 8-K to add required financial information related to its previously reported acquisition of substantially all assets of SiVantage, Inc. The amendment updates Item 9.01 to present the acquired business’s financial statements and the company’s unaudited pro forma financials.
Exhibit 99.1 includes SiVantage’s audited financial statements for the year ended December 31, 2024 and unaudited financial statements for the six months ended June 30, 2025. Exhibit 99.2 provides an unaudited pro forma condensed balance sheet as of June 30, 2025 and unaudited pro forma condensed statements of operations for the year ended December 31, 2024 and the six months ended June 30, 2025. The amendment does not otherwise modify or update the original report.
Tenon Medical, Inc. reported an unregistered issuance of 866,642 restricted stock units (RSUs) to its directors and officers under the company’s 2022 Equity Incentive Plan.
The RSUs vest in two equal tranches, with 50% on January 1, 2026 and 50% on July 31, 2026, and each RSU will convert into one share of common stock upon vesting. The issuance was made in reliance on Section 4(a)(2) of the Securities Act as a private offering.
Tenon Medical (TNON) reported a director equity award. Director Stephen Hochschuler received 21,464 restricted stock units (RSUs) on 10/13/2025 (Form 4, code A). Each RSU represents one share of common stock.
The grant vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The RSUs were reported at a price of $0 and are held directly.
Tenon Medical (TNON) filed a Form 4 reporting an equity award to a director. On 10/13/2025, the reporting person acquired 21,464 restricted stock units (RSUs), each representing the right to receive one share of common stock. The derivative security price is listed as $0.
According to the filing, vesting occurs in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. Following the transaction, 21,464 derivative securities are beneficially owned on a direct basis.
Tenon Medical (TNON) reported an insider equity grant. Director and Chief Technology Officer Richard Ginn received 253,153 restricted stock units (RSUs) on 10/13/2025. Each RSU represents the right to receive one share of common stock.
The RSUs vest in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The filing lists the derivative security price as $0 and indicates direct ownership following the transaction.
Tenon Medical (TNON) reported an insider equity grant on Form 4. Chief Financial Officer and Director Kevin Williamson was awarded 117,974 restricted stock units (RSUs) on 10/13/2025.
Each RSU represents the right to receive one share of common stock. The grant vests in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. Following the reported transaction, 117,974 derivative securities were beneficially owned, held directly.
Tenon Medical (TNON) reported a director equity grant. On 10/13/2025, a director received 21,464 restricted stock units (RSUs) at a price of $0, as disclosed in a Form 4 filing.
Each RSU represents the right to receive one share of common stock. The vesting schedule splits evenly: 50% of the RSUs vest and convert into common stock on January 1, 2026, and the remaining 50% vest and convert on July 31, 2026. Following the grant, the reporting person held 21,464 derivative securities directly.
Tenon Medical (TNON) reported an insider equity award. A director received 20,293 restricted stock units (RSUs) on 10/13/2025, recorded at $0 as typical for RSU grants. Each RSU represents the right to receive one share of common stock.
The award vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026, after which the vested RSUs automatically convert into common shares on a one-for-one basis. Following the reported transaction, the director held 20,293 derivative securities directly.
Tenon Medical (TNON) filed a Form 4 reporting that Director Richard Ferrari received 128,957 restricted stock units (RSUs) on October 13, 2025. Each RSU represents a right to receive one share of common stock. The award vests in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026. The filing lists the transaction at $0 per unit and shows direct ownership of the RSUs following the grant.
Tenon Medical (TNON) disclosed a Form 4 for CEO, President, and Director Steven Foster showing a grant of 281,872 restricted stock units on October 13, 2025. Each RSU represents the right to receive one share of Tenon common stock. The filing states a derivative security price of $0.
The award vests in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. The ownership reported for these derivative securities is Direct.